Measuring preference weights for american college of rheumatology response criteria for patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 32, Issue 12, 2005, Pages 2326-2329

  Chiou, Chiun Fang ^a   Weisman, Michael ^a   Sherbourne, Cathy D ^b   Reyes, Carolina ^c   Dylan, Michelle ^c   Ofman, Joshua ^d   Wallace, Daniel J ^a   Mizutani, Wesley ^e   Suarez Almazor, Maria E ^f  

^a MOUNT SINAI HEALTH SYSTEM   (United States)

^b RAND CORPORATION   (United States)

^c Cerner Health Insights   (United States)

^d AMGEN INC   (United States)

^e Talbert Medical Group   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

American College of Rheumatology response criteria; Rheumatoid arthritis; Toxicity; Utility

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; NEW DRUG;

ABDOMINAL PAIN; ADULT; ARTHRITIS; ARTICLE; ASTHENIA; DISEASE SEVERITY; DIZZINESS; DRUG MONITORING; DRUG SAFETY; DYSPEPSIA; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; ORGANIZATION; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RASH; RHEUMATOID ARTHRITIS; RHINITIS; SEPSIS; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RHEUMATOLOGY; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 28844488177     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Identifying and valuing outcomes. In: Gold M, Siegal I, Russel L, Weinstein M, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996:82-134.
2. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
3. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
4. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
5. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
6. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
7. Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564-70.
8. Wong AL, Wong WK, Harker J, et al. Patient self-report tender and swollen joint counts in early rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. J Rheumatol 1999;26:2551-61.
9. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
10. Bleichrodt H, Johannesson M. Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs. J Health Econ 1997;16:155-75.
11. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item Short-form Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
12. Donald SC, Unutzer J, Schoenbaum M, et al. Can utility-weighted health-related quality-of-life estimates capture health effects of quality improvement for depression? Med Care 2001;39:1246-59.
13. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996;34:702-22.
14. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.